BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 10536465)

  • 1. [Nephrogenic adenoma of the bladder. Morphological and immunophenotypic study with particular attention to differential diagnosis].
    Isimbaldi G; Di Nuovo F; Sironi M; Catania G; Bonacina R; Privitera O; Spinelli M
    Pathologica; 1999 Jun; 91(3):192-7. PubMed ID: 10536465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Undifferentiated small-cell carcinoma of the urinary bladder].
    Suárez Vilela D; Salas Valien JS; González Morán MA; Giménez Pizarro A
    Arch Esp Urol; 1991 Dec; 44(10):1195-8. PubMed ID: 1667892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrogenic adenoma of the urinary bladder--a case report and review of the literature.
    Chosia M; Switała J; Domagała W
    Pol J Pathol; 2002; 53(2):91-5. PubMed ID: 12140873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrogenic adenoma of the urinary tract: a review.
    Alexiev BA; LeVea CM
    Int J Surg Pathol; 2012 Apr; 20(2):123-31. PubMed ID: 22415059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases.
    Ormsby AH; Haskell R; Jones D; Goldblum JR
    Mod Pathol; 2000 Jan; 13(1):46-51. PubMed ID: 10658909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
    Ro JY; Shen SS; Lee HI; Hong EK; Lee YH; Cho NH; Jung SJ; Choi YJ; Ayala AG
    Am J Surg Pathol; 2008 May; 32(5):752-7. PubMed ID: 18379419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivariate analysis DNA/cytokeratin 7 and flow cytometric measurement of MIB-1 in superficial transitional carcinoma of the bladder (TCC). Methodological aspects and prognostic implications.
    Leonardi E; Cristofori A; Reich A; Dalla Palma P
    Eur J Histochem; 1997; 41 Suppl 2():133-4. PubMed ID: 9859817
    [No Abstract]   [Full Text] [Related]  

  • 9. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
    Guo CC; Fine SW; Epstein JI
    Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma.
    Hansel DE; Nadasdy T; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1231-7. PubMed ID: 17667548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
    Tamas EF; Epstein JI
    Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenic adenoma of the bladder in renal transplant and non-renal transplant patients: a review of 22 cases.
    Tse V; Khadra M; Eisinger D; Mitterdorfer A; Boulas J; Rogers J
    Urology; 1997 Nov; 50(5):690-6. PubMed ID: 9372876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
    Cossu-Rocca P; Contini M; Brunelli M; Festa A; Pili F; Gobbo S; Eccher A; Mura A; Massarelli G; Martignoni G
    Am J Surg Pathol; 2009 Jul; 33(7):1031-6. PubMed ID: 19384190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma.
    Hartmann A; Junker K; Dietmaier W; Schröder S; Lopez D; Hofstädter F; Blaszyk H
    Hum Pathol; 2006 Jan; 37(1):117-20. PubMed ID: 16360424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma.
    Herawi M; Drew PA; Pan CC; Epstein JI
    Hum Pathol; 2010 Apr; 41(4):594-601. PubMed ID: 20060152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Two cases of vesical nephrogenic adenoma].
    Tsurukawa H; Komura H; Sasaki H; Iuchi H; Tokumitsu M; Saga Y; Yamaguchi S; Hashimoto H; Yachiku S
    Hinyokika Kiyo; 2003 May; 49(5):285-90. PubMed ID: 12822459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nephrogenic adenoma of the urinary bladder. A lesion that can be confused with carcinoma. Report of 4 cases].
    Rodríguez-Montes CE; Alvarado-Cabrero I
    Gac Med Mex; 2001; 137(1):67-72. PubMed ID: 11244829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Three cases of the nephrogenic adenoma of the bladder].
    Kajita Y; Mizutani Y; Okuno H; Kakehi Y; Terachi T; Yoshida O
    Hinyokika Kiyo; 1998 Sep; 44(9):667-70. PubMed ID: 9805674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
    Lane Z; Hansel DE; Epstein JI
    Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.